Aurinia Pharmaceuticals Inc (AUPH)

[northern vortex]

To those concerned with the terrible SP action of AUPH since VOS was approved by the FDA - Here is an interesting comment by Boston BI provided after an SA article on KPTI. It references AUPH specifically.

Boston Biotech Investor

13 Mar. 2021, 6:15 PM

@Delmar Price I hear you and appreciate the perspective. However we've formally studied all small cap biotechs (with market caps of less than $3Billion) that had their first product approved by the FDA since 1/1/2017. Since 1/1/2020, only 13% of companies (i.e. DCPH, YMAB, BCRX) saw higher share prices 45 days after FDA approval. 87% fell and some rather dramatically (we excluded those approved in 2/2020 from our study...before the COVID panic in 3/2020). Hence unfortunately AUPH's trading pattern is consistent with others getting first approval the last 14 months.

The other material difference to consider is Lupkynis (voclosporin) from AUPH should become the standard of care for Lupus Nephritis relatively quickly. SLE is an awful disease that generally affects women (who we suspect will research current treatment options more aggressively than men). With KPTI's Xpovio, there are multiple multiple competing therapies in the Multiple Myeloma & DLBCL spaces. Though AUPH management is unproven, Lupkynis uptake should be a lay up.